Although the scoring standard and parafibromin antibodies determined the immunohistochemical and predictive sensitivity and specificity of parafibromin expression (Hu et al., 2019), a meta-analysis showed parafibromin loss was found to be more common in PC patients than in those with parathyroid ATA, AD, and hyperplasia. This evidence concerns the gene CDC73 and Alzheimer disease.